The poor efficacy and tolerability of conventional antipsychotic treatment in schizophrenia, together with discovery of …

Schizophrenia continues to be a major healthcare expenditure in our society. Antipsychotic drugs were introduced in the … indirect costs of schizophrenia were estimated to total $US33 billion in 1990. Prior to the approval by the US Food and Drug … Administration (FDA) of clozapine in 1989, no new antipsychotics had been introduced in the US for at least 10 years. Clozapine was …

Relapse of schizophrenia due to poor medication adherence is a major preventable source of psychiatric morbidity. This …

Schizophrenia is a chronic disease that typically manifests during adolescence and early adulthood. Treatment of this … for schizophrenia include both pharmacologic and psychosocial interventions, with antipsychotic therapy (typicals or …-line treatments for patients with newly diagnosed schizophrenia. The newer atypical antipsychotic agents have a lower propensity to …

expenditures related to schizophrenia. Changes in mental health-related utilisation and expenditures over time were calculated … Carolina Medicaid). Patients: Those patients with schizophrenia who received initial prescriptions for risperidone (n = 862 …: Based on these findings, we conclude that, in this population of patients with schizophrenia increased costs associated with …

: (i) high dose antipsychotics; (ii) antipsychotic polypharmacy; (iii) atypical polypharmacy; (iv) multiple `when required …

Background: The California Medicaid Program (Medi-Cal) provided open access to atypical antipsychotics in October 1997 …. This study investigated the impact of open access to atypical antipsychotics on the costs and duration of therapy for … antipsychotics, antidepressants, mood stabilizers, or selected anticonvulsants initiated by patients with bipolar disorders. Episodes …